Top

Published in:

01-10-2017 | Original Contribution

No effects of quercetin from onion skin extract on serum leptin and adiponectin concentrations in overweight-to-obese patients with (pre-)hypertension: a randomized double-blinded, placebo-controlled crossover trial

Authors: Verena Brüll, Constanze Burak, Birgit Stoffel-Wagner, Siegfried Wolffram, Georg Nickenig, Cornelius Müller, Peter Langguth, Birgit Alteheld, Rolf Fimmers, Peter Stehle, Sarah Egert

Published in: European Journal of Nutrition | Issue 7/2017

Abstract

Purpose

Chronic low-level systemic and adipose tissue inflammation has been identified as a major etiologic factor in many chronic diseases, including hypertension and cardiovascular diseases. Evidence from experimental studies suggests anti-inflammatory effects of dietary flavonols such as quercetin.

Methods

We investigated the effects of regular intake of quercetin on leptin, adiponectin, biomarkers of inflammation, glucose and insulin in overweight-to-obese patients with pre- and stage 1 hypertension. Another objective was to assess the safety of daily quercetin supplementation measured by parameters of liver and kidney function and of hematology. Subjects (n = 70) were randomized to receive a supra-nutritional dose of 162 mg/d quercetin or placebo in a double-blinded, placebo-controlled crossover trial with 6-week treatment periods separated by a 6-week washout period. Two subjects dropped out for personal reasons. Only data from the remaining 68 subjects were included in the analysis.

Results

Compared to placebo, quercetin did not significantly affect serum concentrations of leptin and adiponectin, HOMA-AD or the ratios of leptin/adiponectin and adiponectin/leptin. Neither quercetin nor placebo significantly changed serum C-reactive protein and plasma tumor necrosis factor alpha. Compared to placebo, quercetin did not significantly affect glucose, insulin, HOMA-IR, blood biomarkers of liver and renal function, hematology and serum electrolytes.

Conclusion

A supra-nutritional dose of 162 mg/d quercetin from onion skin extract for 6 weeks is safe but without significant effects on parameters of systemic and adipose tissue inflammation as well as glucose and insulin in overweight-to-obese subjects with (pre-)hypertension. This trial was registered at www.germanctr.de/ and http://apps.who.int/trialsearch/ as DRKS00000555.

Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375:132–140CrossRef

Ridker PM (2009) C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem 55:209–215CrossRef

Shai I, Schulze MB, Manson JE, Rexrode KM, Stampfer MJ, Mantzoros C, Hu FB (2005) A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care 28:1376–1382CrossRef

Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351:2599–2610CrossRef

Nakamura K, Fuster JJ, Walsh K (2014) Adipokines: a link between obesity and cardiovascular disease. J Cardiol 63:250–259CrossRef

Lihn AS, Pedersen SB, Richelsen B (2005) Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 6:13–21CrossRef

Swarbrick MM, Havel PJ (2008) Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6:87–102CrossRef

Rojas E, Rodriguez-Molina D, Bolli P, Israili ZH, Faria J, Fidilio E, Bermudez V, Velasco M (2014) The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 16:463CrossRef

Sheng T, Yang K (2008) Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 35:321–326CrossRef

10.

Ouchi N, Walsh K (2008) A novel role for adiponectin in the regulation of inflammation. Arterioscler Thromb Vasc Biol 28:1219–1221CrossRef

11.

Ouchi N, Walsh K (2007) Adiponectin as an anti-inflammatory factor. Clin Chim Acta 380:24–30CrossRef

12.

Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y (2003) Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107:671–674CrossRef

13.

Devaraj S, Torok N, Dasu MR, Samols D, Jialal I (2008) Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 28:1368–1374CrossRef

14.

Huang L, Li C (2000) Leptin: a multifunctional hormone. Cell Res 10:81–92CrossRef

15.

Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770CrossRef

16.

Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A (2015) Differential role of leptin and adiponectin in cardiovascular system. Int J Endocrinol 2015:534320CrossRef

17.

Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 26:1001–1043CrossRef

18.

Wang X, Ouyang YY, Liu J, Zhao G (2013) Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr 111:1–11CrossRef

19.

Erdman JW Jr, Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, Harnly J, Hollman P, Keen CL, Mazza G, Messina M, Scalbert A, Vita J, Williamson G, Burrowes J (2007) Flavonoids and heart health. In: Proceedings of the ILSI North America Flavonoids Workshop, J Nutr 137:718S–737S, May 31–June 1, 2005, Washington, DC

20.

Peterson JJ, Dwyer JT, Jacques PF, McCullough ML (2012) Associations between flavonoids and cardiovascular disease incidence or mortality in European and US populations. Nutr Rev 70:491–508CrossRef

21.

Boots AW, Haenen GR, Bast A (2008) Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585:325–337CrossRef

22.

Boots AW, Wilms LC, Swennen EL, Kleinjans JC, Bast A, Haenen GR (2008) In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 24:703–710CrossRef

23.

Wein S, Behm N, Petersen RK, Kristiansen K, Wolffram S (2010) Quercetin enhances adiponectin secretion by a PPAR-gamma independent mechanism. Eur J Pharm Sci 41:16–22CrossRef

24.

Hoek-van den Hil EF, van Schothorst EM, van Stelt I, Swarts HJ, van Vliet M, Amolo T, Vervoort JJ, Venema D, Hollman PC, Rietjens IM, Keijer J (2015) Direct comparison of metabolic health effects of the flavonoids quercetin, hesperetin, epicatechin, apigenin and anthocyanins in high-fat-diet-fed mice. Genes Nutr 10:469CrossRef

25.

Brüll V, Burak C, Stoffel-Wagner B, Wolffram S, Nickenig G, Muller C, Langguth P, Alteheld B, Fimmers R, Naaf S, Zimmermann BF, Stehle P, Egert S (2015) Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. Br J Nutr 114:1263–1277CrossRef

26.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572CrossRef

27.

Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062CrossRef

28.

Linseisen J, Radtke J, Wolfram G (1997) Flavonoid intake of adults in a Bavarian subgroup of the national food consumption survey. Z Ernahrungswiss 36:403–412CrossRef

29.

Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, van der Schouw YT, Amiano P, Boeing H, Bredsdorff L, Fagherazzi G, Feskens EJ, Franks PW, Grioni S, Katzke V, Key TJ, Khaw KT, Kuhn T, Masala G, Mattiello A, Molina-Montes E, Nilsson PM, Overvad K, Perquier F, Redondo ML, Ricceri F, Rolandsson O, Romieu I, Roswall N, Scalbert A, Schulze M, Slimani N, Spijkerman AM, Tjonneland A, Tormo MJ, Touillaud M, Tumino R, van der AD, van Woudenbergh GJ, Langenberg C, Riboli E, Wareham NJ (2014) Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations. J Nutr 144:335–343CrossRef

30.

Egert S, Wolffram S, Schulze B, Langguth P, Hubbermann EM, Schwarz K, Adolphi B, Bosy-Westphal A, Rimbach G, Müller MJ (2012) Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules. Br J Nutr 107:539–546CrossRef

31.

Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G, Müller MJ (2008) Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr 138:1615–1621

32.

Burak C, Brüll V, Langguth P, Zimmermann BF, Stoffel-Wagner B, Sausen U, Stehle P, Wolffram S, Egert S (2015) Higher plasma quercetin levels following oral administration of an onion skin extract compared with pure quercetin dihydrate in humans. Eur J Nutr Oct 20, 1–11. [Epub ahead of print]

33.

Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ (2005) Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research. Hypertension 45:142–161CrossRef

34.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRef

35.

Masquio DC, de Piano A, Campos RM, Sanches PL, Carnier J, Corgosinho FC, Netto BD, Carvalho-Ferreira JP, Oyama LM, Nascimento CM, de Mello MT, Tufik S, Damaso AR (2015) The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents. Br J Nutr 113:1920–1930CrossRef

36.

Mirza S, Qu HQ, Li Q, Martinez PJ, Rentfro AR, McCormick JB, Fisher-Hoch SP (2011) Adiponectin/leptin ratio and metabolic syndrome in a Mexican American population. Clin Invest Med 34:E290CrossRef

37.

Vega GL, Grundy SM (2013) Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. J Obes 2013:409679CrossRef

38.

Matsuhisa M, Yamasaki Y, Emoto M, Shimabukuro M, Ueda S, Funahashi T, Matsuzawa Y (2007) A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract 77:151–154CrossRef

39.

Bieger J, Cermak R, Blank R, de Boer VC, Hollman PC, Kamphues J, Wolffram S (2008) Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 138:1417–1420

40.

Kenward MG, Jones B (1987) The analysis of data from 2 × 2 cross-over trials with baseline measurements. Stat Med 6:911–926CrossRef

41.

Chuang CC, Martinez K, Xie G, Kennedy A, Bumrungpert A, Overman A, Jia W, McIntosh MK (2010) Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-{alpha}-mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr 92:1511–1521CrossRef

42.

Overman A, Chuang CC, McIntosh M (2011) Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media. Int J Obes (Lond) 35:1165–1172CrossRef

43.

Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M (2008) Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity (Silver Spring) 16:2081–2087CrossRef

44.

Jeong SM, Kang MJ, Choi HN, Kim JH, Kim JI (2012) Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutr Res Pract 6:201–207CrossRef

45.

Kobori M, Masumoto S, Akimoto Y, Oike H (2011) Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res 55:530–540CrossRef

46.

Siriwardhana N, Kalupahana NS, Cekanova M, LeMieux M, Greer B, Moustaid-Moussa N (2013) Modulation of adipose tissue inflammation by bioactive food compounds. J Nutr Biochem 24:613–623CrossRef

47.

Leiherer A, Mundlein A, Drexel H (2013) Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascul Pharmacol 58:3–20CrossRef

48.

Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, Wagner AE, Frank J, Schrezenmeir J, Rimbach G, Wolffram S, Müller MJ (2009) Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 102:1065–1074CrossRef

49.

Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L (2013) Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: a double-blind randomized controlled clinical trial. Int J Prev Med 4:777–785

50.

Zhao G, Etherton TD, Martin KR, Gillies PJ, West SG, Kris-Etherton PM (2007) Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr 85:385–391

51.

Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM (2004) Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 134:2991–2997

52.

Neuhouser ML, Schwarz Y, Wang C, Breymeyer K, Coronado G, Wang CY, Noar K, Song X, Lampe JW (2012) A low-glycemic load diet reduces serum C-reactive protein and modestly increases adiponectin in overweight and obese adults. J Nutr 142:369–374CrossRef

53.

King DE, Egan BM, Woolson RF, Mainous AG III, Al-Solaiman Y, Jesri A (2007) Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. Arch Intern Med 167:502–506CrossRef

54.

Mostowik M, Gajos G, Zalewski J, Nessler J, Undas A (2013) Omega-3 polyunsaturated fatty acids increase plasma adiponectin to leptin ratio in stable coronary artery disease. Cardiovasc Drugs Ther 27:289–295CrossRef

55.

Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, Esposito K, Jonsson LS, Kolb H, Lansink M, Marcos A, Margioris A, Matusheski N, Nordmann H, O’Brien J, Pugliese G, Rizkalla S, Schalkwijk C, Tuomilehto J, Warnberg J, Watzl B, Winklhofer-Roob BM (2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 106(Suppl 3):S5–S78CrossRef

56.

Minihane AM, Vinoy S, Russell WR, Baka A, Roche HM, Tuohy KM, Teeling JL, Blaak EE, Fenech M, Vauzour D, McArdle HJ, Kremer BH, Sterkman L, Vafeiadou K, Benedetti MM, Williams CM, Calder PC (2015) Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr 114:999–1012CrossRef

57.

Pfeuffer MA, Auinger A, Bley U, Kraus-Stojanowic I, Lauce C, Winkler P, Rüfer CE, Frank J, Boesch-Saadatmandi C, Rimbach G, Schrezenmeir J (2013) Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammatory parameters in men with different APOE isoforms. Nutr Metab Cardiovasc Dis 23:403–409CrossRef

58.

Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ (2010) Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 140:278–284CrossRef

59.

Zern TL, Wood RJ, Greene C, West KL, Liu Y, Aggarwal D, Shachter NS, Fernandez ML (2005) Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 135:1911–1917

60.

Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T (2007) Quercetin reduces blood pressure in hypertensive subjects. J Nutr 137:2405–2411

61.

Lee KH, Park E, Lee HJ, Kim MO, Cha YJ, Kim JM, Lee H, Shin MJ (2011) Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers. Nutr Res Pract 5:28–33CrossRef

62.

Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC (2007) A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 45:2179–2205CrossRef

63.

Gamble KL, Berry R, Frank SJ, Young ME (2014) Circadian clock control of endocrine factors. Nat Rev Endocrinol 10:466–475CrossRef

64.

Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55:1954–1960CrossRef

65.

Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Gomez-Perez FJ, Cruz-Bautista I, Arellano-Campos O, Navarrete-Lopez M, Aguilar-Salinas CA (2010) Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance. Cardiovasc Diabetol 9:26CrossRef

Title: No effects of quercetin from onion skin extract on serum leptin and adiponectin concentrations in overweight-to-obese patients with (pre-)hypertension: a randomized double-blinded, placebo-controlled crossover trial
Authors: Verena Brüll
Constanze Burak
Birgit Stoffel-Wagner
Siegfried Wolffram
Georg Nickenig
Cornelius Müller
Peter Langguth
Birgit Alteheld
Rolf Fimmers
Peter Stehle
Sarah Egert
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nutrition / Issue 7/2017
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-016-1267-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2017

Probiotics modulate gut microbiota and health status in Japanese cedar pollinosis patients during the pollen season

Sex- and age-specific percentiles of body composition indices for Chinese adults using dual-energy X-ray absorptiometry

Diet quality and academic achievement: a prospective study among primary school children

The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: a comprehensive review of the literature

Reduced-fat Gouda-type cheese enriched with vitamin D3 effectively prevents vitamin D deficiency during winter months in postmenopausal women in Greece

Monoterpene phenolic compound thymol promotes browning of 3T3-L1 adipocytes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials